Clinical Cancer Research Prevention Award AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gojo, I.
Right arrow Articles by Fenton, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gojo, I.
Right arrow Articles by Fenton, R. G.
Clinical Cancer Research Vol. 8, 3527-3538, November 2002
© 2002 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-11

Ivana Gojo2, Bin Zhang2 and Robert G. Fenton3

Greenebaum Cancer Center, University of Maryland Medical System, Baltimore, Maryland 21201

Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of malignant plasma cells with slow proliferative rate but enhanced survival. MM cells express multiple Bcl-2 family members, including Bcl-2, Bcl-XL, and Mcl-1, which are thought to play a key role in the survival and drug resistance of myeloma. The cyclin-dependent kinase inhibitor flavopiridol has antitumor activity against hematopoietic malignancies, including CLL, in which induction of apoptosis was associated with reduced expression of antiapoptotic proteins. Therefore, we sought to characterize the effect of flavopiridol on the proliferation and survival of myeloma cells and to define its mechanisms of action. Treatment of MM cell lines (8226, ANBL-6, ARP1, and OPM-2) with clinically achievable concentrations of flavopiridol resulted in rapid induction of apoptotic cell death that correlated temporally with the decline in Mcl-1 protein and mRNA levels. Levels of other antiapoptotic proteins did not change. Overexpression of Mcl-1 protected MM cells from flavopiridol-induced apoptosis. Additional analysis demonstrated that flavopiridol treatment resulted in a dose-dependent inhibition of phosphorylation of the RNA polymerase II COOH-terminal domain, thus blocking transcription elongation. These data indicate that Mcl-1 is an important target for flavopiridol-induced apoptosis of MM that occurs through inhibition of Mcl-1 mRNA transcription coupled with rapid protein degradation via the ubiquitin-proteasome pathway.




This article has been cited by other articles:


Home page
 BloodHome page
M. A. Phelps, T. S. Lin, A. J. Johnson, E. Hurh, D. M. Rozewski, K. L. Farley, D. Wu, K. A. Blum, B. Fischer, S. M. Mitchell, et al.
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
Blood, March 19, 2009; 113(12): 2637 - 2645.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Y. Takada, G. Sethi, B. Sung, and B. B. Aggarwal
Flavopiridol Suppresses Tumor Necrosis Factor-Induced Activation of Activator Protein-1, c-Jun N-Terminal Kinase, p38 Mitogen-Activated Protein Kinase (MAPK), p44/p42 MAPK, and Akt, Inhibits Expression of Antiapoptotic Gene Products, and Enhances Apoptosis through Cytochrome c Release and Caspase Activation in Human Myeloid Cells
Mol. Pharmacol., May 1, 2008; 73(5): 1549 - 1557.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Ambrosini, S. L. Seelman, L.-X. Qin, and G. K. Schwartz
The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates the Effects of Topoisomerase I Poisons by Suppressing Rad51 Expression in a p53-Dependent Manner
Cancer Res., April 1, 2008; 68(7): 2312 - 2320.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Zhang, K. Lundgren, Z. Yan, M. E. Arango, S. Price, A. Huber, J. Higgins, G. Troche, J. Skaptason, T. Koudriakova, et al.
Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy
Mol. Cancer Ther., April 1, 2008; 7(4): 818 - 828.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Suvannasankha, C. D. Crean, R. Shanmugam, S. S. Farag, R. Abonour, H. S. Boswell, and H. Nakshatri
Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide
Clin. Cancer Res., March 15, 2008; 14(6): 1814 - 1822.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S.-R. A. Hussain, D. M. Lucas, A. J. Johnson, T. S. Lin, A. P. Bakaletz, V. X. Dang, S. Viatchenko-Karpinski, A. S. Ruppert, J. C. Byrd, P. Kuppusamy, et al.
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
Blood, March 15, 2008; 111(6): 3190 - 3199.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
E. F. Lee, P. E. Czabotar, M. F. van Delft, E. M. Michalak, M. J. Boyle, S. N. Willis, H. Puthalakath, P. Bouillet, P. M. Colman, D. C.S. Huang, et al.
A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation
J. Cell Biol., January 28, 2008; 180(2): 341 - 355.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. M. Stellrecht, C. J. Phillip, F. Cervantes-Gomez, and V. Gandhi
Multiple Myeloma Cell Killing by Depletion of the MET Receptor Tyrosine Kinase
Cancer Res., October 15, 2007; 67(20): 9913 - 9920.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Karp, B. D. Smith, M. J. Levis, S. D. Gore, J. Greer, C. Hattenburg, J. Briel, R. J. Jones, J. J. Wright, and A. D. Colevas
Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia
Clin. Cancer Res., August 1, 2007; 13(15): 4467 - 4473.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Gomez-Bougie, S. Wuilleme-Toumi, E. Menoret, V. Trichet, N. Robillard, M. Philippe, R. Bataille, and M. Amiot
Noxa Up-regulation and Mcl-1 Cleavage Are Associated to Apoptosis Induction by Bortezomib in Multiple Myeloma
Cancer Res., June 1, 2007; 67(11): 5418 - 5424.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. B. Baughn, M. Di Liberto, K. Wu, P. L. Toogood, T. Louie, R. Gottschalk, R. Niesvizky, H. Cho, S. Ely, M. A.S. Moore, et al.
A novel orally active small molecule potently induces g1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
Cancer Res., August 1, 2006; 66(15): 7661 - 7667.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
N. Gao, L. Kramer, M. Rahmani, P. Dent, and S. Grant
The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 through a Transcriptional Mechanism
Mol. Pharmacol., August 1, 2006; 70(2): 645 - 655.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. A. Gomez, A. de las Pozas, and C. Perez-Stable
Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1216 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. I. Shapiro
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
J. Clin. Oncol., April 10, 2006; 24(11): 1770 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
S. Grant
Nuclear Acetylation Targets: NF-{kappa}B and the ROS Connection
Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 322 - 326.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Derouet, L. Thomas, D. A. Moulding, C. Akgul, A. Cross, R. J. Moots, and S. W. Edwards
Sodium Salicylate Promotes Neutrophil Apoptosis by Stimulating Caspase-Dependent Turnover of Mcl-1
J. Immunol., January 15, 2006; 176(2): 957 - 965.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Stromberg, S. Ekman, L. Girnita, L. Y. Dimberg, O. Larsson, M. Axelson, J. Lennartsson, U. Hellman, K. Carlson, A. Osterborg, et al.
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells
Blood, January 15, 2006; 107(2): 669 - 678.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Cai, K. F. Byth, and G. I. Shapiro
AZ703, an Imidazo[1,2-a]Pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9
Cancer Res., January 1, 2006; 66(1): 435 - 444.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Dasmahapatra, J. A. Almenara, and S. Grant
Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells That Overexpress Bcl-2
Mol. Pharmacol., January 1, 2006; 69(1): 288 - 298.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Karp, A. Passaniti, I. Gojo, S. Kaufmann, K. Bible, T. S. Garimella, J. Greer, J. Briel, B. D. Smith, S. D. Gore, et al.
Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-{beta}-D-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias
Clin. Cancer Res., December 1, 2005; 11(23): 8403 - 8412.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Rahmani, E. M. Davis, C. Bauer, P. Dent, and S. Grant
Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation
J. Biol. Chem., October 21, 2005; 280(42): 35217 - 35227.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Chen, M. J. Keating, V. Gandhi, and W. Plunkett
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
Blood, October 1, 2005; 106(7): 2513 - 2519.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Raje, S. Kumar, T. Hideshima, A. Roccaro, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Chauhan, N. C. Munshi, S. R. Green, et al.
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
Blood, August 1, 2005; 106(3): 1042 - 1047.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
E. W. Newcomb, M. A. Ali, T. Schnee, L. Lan, Y. Lukyanov, M. Fowkes, D. C. Miller, and D. Zagzag
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1{alpha} expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy
Neuro-oncol, July 1, 2005; 7(3): 225 - 235.
[Abstract] [PDF]

Home page
 Ann OncolHome page
K. Lacrima, A. Valentini, C. Lambertini, M. Taborelli, A. Rinaldi, E. Zucca, C. Catapano, F. Cavalli, A. Gianella-Borradori, D. E. MacCallum, et al.
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas
Ann. Onc., July 1, 2005; 16(7): 1169 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. L. Bergsagel, W. M. Kuehl, F. Zhan, J. Sawyer, B. Barlogie, and J. Shaughnessy Jr
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Blood, July 1, 2005; 106(1): 296 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D. P. Lane, and S. R. Green
Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II-Dependent Transcription and Down-regulation of Mcl-1
Cancer Res., June 15, 2005; 65(12): 5399 - 5407.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. N. Bhalla
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
R Rust, G Harms, T Blokzijl, M Boot, A Diepstra, J Kluiver, L Visser, S-C Peh, M Lim, W A Kamps, et al.
High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma
J. Clin. Pathol., May 1, 2005; 58(5): 520 - 524.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
C. M. Stellrecht, L. S. Chen, and V. Gandhi
Inhibition of Oncogene Expression by RNA-Directed Agents
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 338 - 343.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Gauduchon, F. Gouilleux, S. Maillard, V. Marsaud, J.-M. Renoir, and B. Sola
4-Hydroxytamoxifen Inhibits Proliferation of Multiple Myeloma Cells In vitro through Down-Regulation of c-Myc, Up-Regulation of p27Kip1, and Modulation of Bcl-2 Family Members
Clin. Cancer Res., March 15, 2005; 11(6): 2345 - 2354.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
D.P. LANE
Exploiting the p53 Pathway for the Diagnosis and Therapy of Human Cancer
Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 489 - 497.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X.-Y. Pei, Y. Dai, and S. Grant
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism
Mol. Cancer Ther., December 1, 2004; 3(12): 1513 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood, August 1, 2004; 104(3): 607 - 618.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Dai, M. Rahmani, X.-Y. Pei, P. Dent, and S. Grant
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms
Blood, July 15, 2004; 104(2): 509 - 518.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Grant and P. Dent
Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name?
Mol. Cancer Ther., July 1, 2004; 3(7): 873 - 875.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Derouet, L. Thomas, A. Cross, R. J. Moots, and S. W. Edwards
Granulocyte Macrophage Colony-stimulating Factor Signaling and Proteasome Inhibition Delay Neutrophil Apoptosis by Increasing the Stability of Mcl-1
J. Biol. Chem., June 25, 2004; 279(26): 26915 - 26921.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. N. Demidenko and M. V. Blagosklonny
Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor
Cancer Res., May 15, 2004; 64(10): 3653 - 3660.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Camphausen, K. J. Brady, W. E. Burgan, M. A. Cerra, J. S. Russell, E. E.A. Bull, and P. J. Tofilon
Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of {gamma}H2AX foci
Mol. Cancer Ther., April 1, 2004; 3(4): 409 - 416.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Ikezoe, T. Saito, K. Bandobashi, Y. Yang, H. P. Koeffler, and H. Taguchi
HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2
Mol. Cancer Ther., April 1, 2004; 3(4): 473 - 479.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
R. R. Rosato, J. A. Almenara, C. Yu, and S. Grant
Evidence of a Functional Role for p21WAF1/CIP1 Down-Regulation in Synergistic Antileukemic Interactions between the Histone Deacetylase Inhibitor Sodium Butyrate and Flavopiridol
Mol. Pharmacol., March 1, 2004; 65(3): 571 - 581.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Takada and B. B. Aggarwal
Flavopiridol Inhibits NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Agents through Inhibition of I{kappa}B{alpha} Kinase and p65 Phosphorylation: ABROGATION OF CYCLIN D1, CYCLOOXYGENASE-2, AND MATRIX METALLOPROTEASE-9
J. Biol. Chem., February 6, 2004; 279(6): 4750 - 4759.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. W. C. J. van de Donk, M. M. J. Kamphuis, B. van Kessel, H. M. Lokhorst, and A. C. Bloem
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels
Blood, November 1, 2003; 102(9): 3354 - 3362.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot
Advances in Biology and Therapy of Multiple Myeloma
Hematology, January 1, 2003; 2003(1): 248 - 278.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.